07.09.2014

Helmut Buschmann is Awarded the 2014 IUPAC-Richter Prize

The 2014 IUPAC-Richter Prize in Medicinal Chemistry has been awarded to AiCuris' Head of Chemistry & Patents, Dr. Helmut Buschmann.

Helmut Buschmann is Awarded the 2014 IUPAC-Richter Prize


Lissabon, 07. September 2014


The 2014 IUPAC-Richter Prize in Medicinal Chemistry has been awarded to Dr. Helmut Buschmann. Dr. Buschmann received this award in recognition of his outstanding creative contributions to the invention, discovery and development of the novel analgesic drug tapentadol (Nucynta™, Palexia™), first approved in 2008.


The IUPAC-Richter Prize, comprising a plaque and a check for USD 10,000, will be presented on September 7-11, 2014 at the 23rd European Federation of Medicinal Chemistry International Symposium in Lisbon, Portugal. The plaque will be signed by Dr. Mark Cesa, President of IUPAC, Erik Bogsch, Chief Executive Officer of Gedeon Richter plc (Budapest, Hungary), and Professor Robin Ganellin, Chair of the IUPAC-Richter Prize selection committee. Dr. Buschmann will present a lecture at this Symposium and also, on May 21, at the American Chemical Society 34th National Medicinal Symposium in Charleston, SC.


Helmut Buschmann studied chemistry at the Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Germany and also obtained his PhD there, in organic synthesis, with Prof. Hans-Dieter Scharf. He started his career in pharmaceutical research in 1992 at Grünenthal GmbH, Aachen, becoming Head of the Department of Synthetic Chemistry in 1996, and then, in 2001, Head of Chemical Research.


From 2002 to 2008 he was Research Director of Laboratories Dr. Esteve, Barcelona. Since then he has been teaching medicinal chemistry at the RWTH Aachen. He is also a member of Pharma Consulting Aachen and is Chief Scientific Officer of Savira Pharmaceuticals GmbH.


Gedeon Richter Plc. founded in 1901 and headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter’s consolidated sales were approximately EUR 1.1 billion (USD 1.5 billion) while its market capitalization amounted to EUR 2.3 billion (USD 3.1 billion) in 2012. The product portfolio of the Company covers almost all important therapeutic areas, including gynaecology, central nervous system and cardiovascular. Having the largest R&D unit in Central Eastern Europe, the Company’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise Richter is a significant player in the female healthcare field worldwide. Richter is also active in the scope of biosimilar product development. More information about Gedeon Richter Plc. and its activities is available at <http://www.richter.hu>.

 


back